Progress in Medicinal Chemistry - 1st Edition - ISBN: 9780444642776

Progress in Medicinal Chemistry, Volume 58

1st Edition

Serial Editors: David Witty Brian Cox
Hardcover ISBN: 9780444642776
Imprint: Elsevier
Published Date: 8th March 2019
Page Count: 260
Sales tax will be calculated at check-out Price includes VAT/GST

Institutional Subscription

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Table of Contents

1. Amyotrophic lateral sclerosis (ALS)
Klara Valko
2. Covelent-binding Drugs
Anil Vasudevan
3. Natural Product Drug Delivery – A Special Challenge?
Neil Press
4. SMN2 gene splicing modifier
Hasane Ratni


Description

Progress in Medicinal Chemistry, Volume 58 provides a review of eclectic developments in medicinal chemistry, with each chapter written by an international board of authors. Topics covered in this new release include Amyotrophic lateral sclerosis (ALS), Covalent-binding Drugs, Natural Product Drug Delivery – A Special Challenge?, and SMN2 gene splicing modifier, and more.

Key Features

  • Provides extended, timely reviews of topics in medicinal chemistry
  • Contains targets and technologies relevant to the discovery of tomorrow’s drugs
  • Presents analyses of successful drug discovery programs

Readership

Everyone interested in the strategy and practice of the preclinical phases of the creation of new medicines. Those wishing to understand the drivers of drug design or expand their knowledge of therapeutic target classes


Details

No. of pages:
260
Language:
English
Copyright:
© Elsevier 2019
Published:
Imprint:
Elsevier
Hardcover ISBN:
9780444642776

Ratings and Reviews


About the Serial Editors

David Witty

David Witty Serial Editor

Dr David Witty has more than 20 years experience in the pharmaceutical industry as a medicinal chemist and project leader working principally in areas of anti-infectives, metabolic diseases, cognition and pain, delivering clinical candidates for several conditions. He led IT Strategy within the Neurology division of GSK, developing and deploying the first Electronic Notebooks for drug discovery to sites in the UK and Singapore. He has contributed more than 90 scientific papers, reviews, patents and books on medicinal and synthetic chemistry.

In 2010 David and several colleagues successfully raised $35M in venture funding to found Convergence Pharmaceuticals, a specialist ion channel company focused on the development of novel treatments for pain, based in Cambridge UK. David presently leads their discovery programme and manages scientific operations within the business.

David is chairman of the Fine Chemicals Group of the Society of Chemical Industry, with responsibility for the delivery of conferences, seminars and training courses for chemists throughout the UK and Europe, and advising parliamentary bodies on matters of relevance to the UK chemical industry.

Since 2008 David has been a STEM ambassador for SETPOINT, introducing school students at both primary and secondary level to the excitement and possibilities of pursuing scientific careers, through workshops, lectures and competitions.

Affiliations and Expertise

WITNET LTD, Cambridge, UK

Brian Cox Serial Editor

Professor Brian Cox is at University of Sussex, Brighton, UK

Affiliations and Expertise

University of Sussex, Brighton, UK